Cargando…

Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors

Dendritic cells mediate innate and adaptive immune responses and are directly involved in the activation of cytotoxic T lymphocytes that kill tumor cells. Dendritic cell-based cancer immunotherapy has clinical benefits. Dendritic cell subsets are diverse, and tumors can be hot or cold, depending on...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Byeong Hoon, Lee, Heung Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266676/
https://www.ncbi.nlm.nih.gov/pubmed/35806328
http://dx.doi.org/10.3390/ijms23137325
_version_ 1784743526623346688
author Kang, Byeong Hoon
Lee, Heung Kyu
author_facet Kang, Byeong Hoon
Lee, Heung Kyu
author_sort Kang, Byeong Hoon
collection PubMed
description Dendritic cells mediate innate and adaptive immune responses and are directly involved in the activation of cytotoxic T lymphocytes that kill tumor cells. Dendritic cell-based cancer immunotherapy has clinical benefits. Dendritic cell subsets are diverse, and tumors can be hot or cold, depending on their immunogenicity; this heterogeneity affects the success of dendritic cell-based immunotherapy. Here, we review the ontogeny of dendritic cells and dendritic cell subsets. We also review the characteristics of hot and cold tumors and briefly introduce therapeutic trials related to hot and cold tumors. Lastly, we discuss dendritic cell-based cancer immunotherapy in hot and cold tumors.
format Online
Article
Text
id pubmed-9266676
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92666762022-07-09 Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors Kang, Byeong Hoon Lee, Heung Kyu Int J Mol Sci Review Dendritic cells mediate innate and adaptive immune responses and are directly involved in the activation of cytotoxic T lymphocytes that kill tumor cells. Dendritic cell-based cancer immunotherapy has clinical benefits. Dendritic cell subsets are diverse, and tumors can be hot or cold, depending on their immunogenicity; this heterogeneity affects the success of dendritic cell-based immunotherapy. Here, we review the ontogeny of dendritic cells and dendritic cell subsets. We also review the characteristics of hot and cold tumors and briefly introduce therapeutic trials related to hot and cold tumors. Lastly, we discuss dendritic cell-based cancer immunotherapy in hot and cold tumors. MDPI 2022-06-30 /pmc/articles/PMC9266676/ /pubmed/35806328 http://dx.doi.org/10.3390/ijms23137325 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kang, Byeong Hoon
Lee, Heung Kyu
Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors
title Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors
title_full Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors
title_fullStr Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors
title_full_unstemmed Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors
title_short Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors
title_sort dendritic cell-based immunotherapy in hot and cold tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266676/
https://www.ncbi.nlm.nih.gov/pubmed/35806328
http://dx.doi.org/10.3390/ijms23137325
work_keys_str_mv AT kangbyeonghoon dendriticcellbasedimmunotherapyinhotandcoldtumors
AT leeheungkyu dendriticcellbasedimmunotherapyinhotandcoldtumors